Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + melphalan + rabbit antithymocyte globulin
- Development stage
- Unknown
- Lead developer
- University of Chicago
- Modality
- Small Molecules, Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a reduced-intensity conditioning (RIC) regimen developed by the University of Chicago, specifically designed for patients undergoing combined haploidentical and umbilical cord blood stem cell transplantation (Haplo-Cord). The regimen consists of fludarabine (a purine analog chemotherapy), melphalan (a nitrogen mustard alkylating agent), and rabbit antithymocyte globulin (r-ATG, often administered as Thymoglobulin). Fludarabine and melphalan provide cytoreduction and myelosuppression to facilitate donor cell engraftment, while r-ATG provides potent T-cell depletion to prevent graft-versus-host disease (GVHD) and reduce the risk of graft rejection. This protocol is utilized for a wide range of hematologic conditions, including acute and chronic leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes, and non-malignant disorders like aplastic anemia and hemoglobinopathies in both adult and pediatric populations.
- Other names
- Flu/Mel/r-ATGFludarabine-Melphalan-rATGUniversity of Chicago conditioning regimen
02
Targets
DNADNA polymerase familyRNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on fludarabine + melphalan + rabbit antithymocyte globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + melphalan + rabbit antithymocyte globulin.